Xcellerex commences construction of new cGMP FlexFactory biomanufacturing facility at Marlborough

Xcellerex, Inc. announced today that it has begun construction of a state-of-the-art cGMP FlexFactory® biomanufacturing facility at its headquarters location in Marlborough, Massachusetts. Construction will be completed in September 2010. The facility, the second FlexFactory at the company's headquarters site, will expand Xcellerex's capacity to provide bridge biomanufacturing services for clients that are planning or building their own FlexFactory facilities. The plant will also support Xcellerex's contract manufacturing operations.

“The timeline in which we will bring this cGMP facility online will dramatically underscore the leap in deployment speed that FlexFactory enables.”

Xcellerex President and CEO Guy Broadbent commented, "This facility represents an important milestone for Xcellerex. First, it reflects the surge in interest we are seeing in the FlexFactory platform. The new plant will enable our biomanufacturing services group to support the increased demand for transitional biomanufacturing that we offer to help speed client deployments of their new FlexFactory installations. Second, this will provide a working showcase to demonstrate FlexFactory to the many customers who have expressed interest in evaluating the platform for their next capacity investment." Finally, he noted, "The timeline in which we will bring this cGMP facility online will dramatically underscore the leap in deployment speed that FlexFactory enables."

Xcellerex founder and Chief Technology Officer Parrish Galliher added, "This new FlexFactory facility in Marlborough will be a great case study, demonstrating the power of the FlexFactory capability. We will achieve new working capacity in less than six months, at a fraction of the cost required for a conventional facility. This will also give us a hands-on educational tool to help prospective customers achieve a deeper understanding of how a FlexFactory operates."

The new facility will feature 2,000 liter Xcellerex XDR single-use bioreactors and modular single-use downstream unit operations through bulk-product.

SOURCE Xcellerex, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.